News

Sigma-Tau is developing this product as an emergency treatment for severe and complicated malaria in collaboration with the Walter Reed Army Institute of Research. Gregg Lapointe, Sigma-Tau Pharmaceutical’s

The clinical trial design included five escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a

These expanded label claims allow blood banks in Europe to use the Intercept Blood System in place of gamma irradiation for the prevention of transfusion-associated graft-vs.-host disease (TA-GVHD).

The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase – a clinically-validated cancer target – formulated with

The laboratory will place Orchid Cellmark close to its customers in the North West of England and is expected to provide expansion capacity to accommodate the award as

The approval follows a successful clinical trial involving more than 450 bridge-to-transplantation (BTT) patients, including those enrolled under continued access protocols, and a unanimous recommendation for approval from

The Stockert S5 is the fifth-generation of heart-lung machines and the successor to Sorin Group’s SIII perfusion system. The company claims that the S5 technology sets new standards

Surgical Care Affiliates’s (SCA’s) current president and CEO, Mike Snow, is resigning his position effective April 30, 2008, but will continue to serve as an advisor on the

The acquisition of the Xenon CT Perfusion technology is said to enhance NeuroLogica’s Portable CT capabilities in the emergency room, intensive care unit and operating room while increasing